{"classes":[{"categories":[{"measurements":[{"comment":"Insufficient number of events to calculate median and upper limit number.","groupId":"OG000","lowerLimit":"11.01","upperLimit":"NA","value":"NA"},{"comment":"Insufficient number of events to calculate upper limit number.","groupId":"OG001","lowerLimit":"2.69","upperLimit":"NA","value":"11.14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"TMB: <7"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.06","upperLimit":"39.43","value":"38.67"},{"comment":"Insufficient number of events to calculate upper limit number.","groupId":"OG001","lowerLimit":"2.79","upperLimit":"NA","value":"8.59"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"TMB ≥ 7"},{"categories":[{"measurements":[{"comment":"Insufficient number of events to calculate upper limit number and median","groupId":"OG000","lowerLimit":"3.06","upperLimit":"NA","value":"NA"},{"comment":"Insufficient number of events to calculate upper limit number.","groupId":"OG001","lowerLimit":"4.17","upperLimit":"NA","value":"11.14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"TMB: <10"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.87","upperLimit":"38.67","value":"38.67"},{"groupId":"OG001","lowerLimit":"2.79","upperLimit":"12.29","value":"7.54"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"TMB: ≥ 10"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.93","upperLimit":"26.71","value":"26.71"},{"groupId":"OG001","lowerLimit":"4.14","upperLimit":"14.29","value":"8.21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"TMB: Not Reported"}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"description":"The time between the date of first confirmed response to the date of the first documented tumor progression, or death due to any cause, whichever occurs first.\n\nTumor Mutational Burden (TMB) refers to the number of nonsynonymous somatic mutations that exist within a tumor's genome as measured by the Foundation One CDx panel at Foundation Medicine. The analysis was done on subjects with baseline tumor mutation burden by a cutoff of 7 mutations/megabase (mut/Mb) and 10 mut/Mb","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with histologically confirmed Squamous Cell Carcinoma of the Head and Neck (SCCHN) that has recurred during or less than 6 months after completion of previous platinum-based chemotherapy.\n\nTreated with Nivolumab 3 mg/kg Q2W + Ipilimumab 1 mg/kg Q6W","id":"OG000","title":"Treatment A - Platinum Refractory Subgroup"},{"description":"Participants with histologically confirmed Squamous Cell Carcinoma of the Head and Neck (SCCHN) that has recurred during or less than 6 months after completion of previous platinum-based chemotherapy.\n\nTreated with Nivolumab 3 mg/kg Q2W + Ipilimumab-Placebo Q6W","id":"OG001","title":"Treatment B - Platinum Refractory Subgroup"}],"paramType":"MEDIAN","populationDescription":"All treated participants in the Platinum Refractory subgroup with a response","reportingStatus":"POSTED","timeFrame":"From randomization to disease progression or death. Approximately 63 Months","title":"Duration of Response (DOR) - Platinum Refractory Subgroup Based on Tumor Mutation Burden (TMB) Status","type":"SECONDARY","unitOfMeasure":"Months"}